Investment Management

Innovative products and solutions across the liquidity spectrum

Digital Health

The convergence of technology, retail and health care


The leading voice in life sciences


Insights into the world’s most dynamic companies

Featured News

Corporate Access & Conferences

Connecting companies with the investment community

Ritu Baral initiates coverage of $ALBO, a biotech focused on the development of bile acid modulators drug candidates


Ahead of the Curve

Jun 30 2017

Biotech – Cowen Analysis: When Insiders Buy, Investors Should Too

Cowen analyzed 4K+ open market transactions made by insiders at the 10 largest biotechnology companies over the last 10 years. We find that purchases by insiders are a strong predictor of outperformance, while stock sales by insiders have little predictive value. When insiders purchase shares of fundamentally strong companies, a successful strategy would seem to be to buy right along with them.
Featured Profile
“The sell side is high energy and I love the 'work hard/play hard' culture.”
Jean Perreault, Vice President, Research
Featured Profile
“Day to day, I work with all of the business groups and teams within Cowen, either directly or behind the scenes.”
Peggy Finster, Managing Director, Labor and Employment Counsel
Featured Profile
“We worked on the Trivago IPO, the Facebook IPO, the sale of Living Social to Groupon and the Wayfair IPO.”
Jose A. Cobos, Managing Director, Technology, Media and Telecom
Featured Profile
“We've built a large, generalist platform that gives me an opportunity to interact with more clients.”
David Rountree, Managing Director, Equity Sales